Coeptis Therapeutics Holdings, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
COEP Nasdaq 2830 coeptistx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coeptis Therapeutics Holdings, Inc.

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology - May 28th, 2025 6:28 am
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline - Mar 11th, 2025 6:34 am
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan - Mar 7th, 2025 6:37 am
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing - Feb 20th, 2025 5:27 am
Coeptis Therapeutics (COEP): Launching AI-Focused Venture Arm to Fuel Innovation - Feb 13th, 2025 1:33 pm
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups - Feb 13th, 2025 6:39 am
Coeptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations - Feb 8th, 2025 12:35 am
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration - Feb 6th, 2025 6:08 am
Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation - Jan 31st, 2025 8:12 am
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation - Jan 30th, 2025 6:27 am
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation - Jan 23rd, 2025 6:09 am
Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Jan 22nd, 2025 6:00 am
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform - Jan 7th, 2025 6:00 am
Why Is Coeptis Therapeutics Stock Falling On Friday? - Dec 27th, 2024 10:09 am
Coeptis Therapeutics Announces Reverse Stock Split - Dec 27th, 2024 6:15 am
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies - Dec 26th, 2024 6:15 am
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies - Dec 12th, 2024 6:00 am
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries - Dec 3rd, 2024 6:15 am
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development - Nov 7th, 2024 6:07 am
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use - Oct 24th, 2024 6:07 am